elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35090804-7B73F77E-6594-4448-A367-9F40E6A080EB
Q35090804-7B73F77E-6594-4448-A367-9F40E6A080EB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35090804-7B73F77E-6594-4448-A367-9F40E6A080EB
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
P2860
Q35090804-7B73F77E-6594-4448-A367-9F40E6A080EB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35090804-7B73F77E-6594-4448-A367-9F40E6A080EB
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
9a9af5ca7343e1ab535fa70350c366d120bff029
P2860
ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.